208 related articles for article (PubMed ID: 34009303)
1. Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery.
Marchegiani G; Pollini T; Andrianello S; Tomasoni G; Biancotto M; Javed AA; Kinny-Köster B; Amini N; Han Y; Kim H; Kwon W; Kim M; Perri G; He J; Bassi C; Goh BK; Katz MH; Jang JY; Wolfgang C; Salvia R
JAMA Surg; 2021 Jul; 156(7):654-661. PubMed ID: 34009303
[TBL] [Abstract][Full Text] [Related]
2. Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features.
Kolb JM; Argiriadi P; Lee K; Liu X; Bagiella E; Gupta S; Lucas AL; Kim MK; Kumta NA; Nagula S; Sarpel U; DiMaio CJ
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1481-1487. PubMed ID: 29535058
[TBL] [Abstract][Full Text] [Related]
3. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
[TBL] [Abstract][Full Text] [Related]
4. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
5. Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium.
Kerlakian S; Dhar VK; Abbott DE; Kooby DA; Merchant NB; Kim HJ; Martin RC; Scoggins CR; Bentrem DJ; Weber SM; Maithel SK; Ahmad SA; Patel SH
HPB (Oxford); 2019 Apr; 21(4):482-488. PubMed ID: 30361110
[TBL] [Abstract][Full Text] [Related]
6. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
[TBL] [Abstract][Full Text] [Related]
7. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
8. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
[TBL] [Abstract][Full Text] [Related]
10. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
11. Uncinate Duct Dilatation Predicts Additional Risk for High-Grade Dysplasia or Invasive Carcinoma Among Fukuoka-Positive Intraductal Papillary Mucinous Neoplasms.
Yang AZ; Kongboonvijit S; Fernandez-Del Castillo CF; Fong ZV; Zelga PJ; Ferrone CR; Lillemoe KD; Kambadakone A; Qadan M
Ann Surg; 2023 Jun; 277(6):988-994. PubMed ID: 36804283
[TBL] [Abstract][Full Text] [Related]
12. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
[TBL] [Abstract][Full Text] [Related]
13. Are the Current Guidelines for the Surgical Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas Adequate? A Multi-Institutional Study.
Wilson GC; Maithel SK; Bentrem D; Abbott DE; Weber S; Cho C; Martin RC; Scoggins CR; Kim HJ; Merchant NB; Kooby DA; Edwards MJ; Ahmad SA
J Am Coll Surg; 2017 Apr; 224(4):461-469. PubMed ID: 28088598
[TBL] [Abstract][Full Text] [Related]
14. Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas.
Han Y; Kwon W; Lee M; Jung HS; Yun WG; Cho YJ; Chae YS; Fernández-Del Castillo C; Marchegiani G; Salvia R; Goh BKP; Lee WJ; Jang JY
JAMA Surg; 2024 Apr; 159(4):389-396. PubMed ID: 38231494
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
16. Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.
Lattimore CM; Kane WJ; Subbarao S; Venitti C; Cramer CL; Turkheimer LM; Bauer TW; Turrentine FE; Zaydfudim VM
J Surg Oncol; 2023 Dec; 128(7):1087-1094. PubMed ID: 37530526
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Capurso G; Crippa S; Vanella G; Traini M; Zerboni G; Zaccari P; Belfiori G; Gentiluomo M; Pessarelli T; Petrone MC; Campa D; Falconi M; Arcidiacono PG
JAMA Netw Open; 2020 Nov; 3(11):e2022933. PubMed ID: 33252689
[TBL] [Abstract][Full Text] [Related]
18. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
19. Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
Han Y; Lee H; Kang JS; Kim JR; Kim HS; Lee JM; Lee KB; Kwon W; Kim SW; Jang JY
Gastroenterology; 2018 Feb; 154(3):576-584. PubMed ID: 29074452
[TBL] [Abstract][Full Text] [Related]
20. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
